Long-lasting complete remission in a patient with systemic metastases of recurrent breast cancer treated with cyclin-dependent kinases 4/6 inhibitors: a case report

Journal of Medical Case Reports

Case Report

Yasutaka Takeda¹  Kenichiro Hasumi²  Nastuki Seki²  Toshihiko Yoneto³  Takayuki Yoshimoto⁴  Nobukazu Takahashi⁵ 

[1] Breast Oncology Center, Fukujuji Hospital, 3-1-24 Matsuyama, 204-8522, Kiyose, Tokyo, Japan;Department of Breast Surgery, Hijirigaoka Hospital, Tama City, 2-69-6 Renkōji, 206-0021, Tokyo, Japan;Department of Breast Surgery, Hijirigaoka Hospital, Tama City, 2-69-6 Renkōji, 206-0021, Tokyo, Japan;Department of Breast Surgery and Oncology, Nippon Medical School, Chiba Hokusou Hospital, 1715 Kamagari, Inzai City, 270-1694, Chiba, Japan;Department of Immunoregulation, Institute of Medical Science, Tokyo Medical University, 6-1-1 Shinjuku, Shinjuku-Ku, 160-8402, Tokyo, Japan;Department of Immunoregulation, Institute of Medical Science, Tokyo Medical University, 6-1-1 Shinjuku, Shinjuku-Ku, 160-8402, Tokyo, Japan;Department of Surgery, Oguchihigashi General Hospital, 2-19-1 Irie, Kanagawa-Ku, 221-0014, Yokohama, Kanagawa, Japan;

关键词: Breast cancer;    CDK4/6 inhibitors;    Complete remission;    Immune systems;    Immunosenescent T cell;    Recurrence;   

DOI  :  10.1186/s13256-023-03902-4

 received in 2022-10-24, accepted in 2023-03-20,  发布年份 2023

来源: Springer

【 摘 要 】

BackgroundThe prognosis for recurrence cases of hormone receptor-positive HER2-negative breast cancer remains poor, and treatment strategies that emphasize quality of life have often been chosen, with few physicians aiming for a cure. Our objective is to assess the validity of such current treatment strategies.Case presentationA 74-year-old Asian woman with multiple lung and liver metastases after local recurrence of breast cancer was treated with two different cyclin-dependent kinases 4/6 inhibitors sequentially in combination with endocrine therapy. Flow cytometric analysis of the patient’s peripheral blood mononuclear cells was also performed to evaluate the host’s immune status. Complete remission was achieved without cytotoxic agents and the patient remains disease free to this day, 6 years after the initial relapse. Additionally, no increase in the population of the immunosenescent T cells with a phenotype of CD8+CD28− was observed in the patient’s peripheral blood mononuclear cells, suggesting that the immune system was well maintained.ConclusionsWe present this case study to develop new treatment strategies for recurrent breast cancer that is not only bound to misinterpretations of the Hortobagyi algorithm, but also aim for a cure with noncytotoxic agents to maintain the host’s immune system and early detection of recurrence.

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

41116_2023_36_Article_IEq684.gif

Fig. 1